Welcome to the e-CCO Library!

OP17: Impact of phenotypic and genetic factors on Crohn’s Disease evolution in a cohort of 13,926 patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Zhang, Q.(1);Fachal, L.(1);Shawky, R.(2);Parkes, M.(2,3,4);Anderson, C.(1);Raine, T.(1,4)
Created: Wednesday, 2 June 2021, 4:12 PM
OP17: Maintenance phase propensity score adjusted effectiveness and persistence at week-52 in biologic-naïve Ulcerative Colitis patients treated with vedolizumab or anti-TNF (VEDO IBD-study)
Year: 2022
Source: ECCO'22
Authors: Plachta-Danielzik, S.(1);di Giuseppe, R.(2);Bokemeyer, B.(3);Efken, P.(4);Mohl, W.(5);Krause, T.(6);Hoffstadt, M.(7);Ehehalt, R.(8);Trentmann, L.(9);Schweitzer, A.(10);Jessen, P.(11);Franzenburg, S.(1);Hartmann, P.(4);Schreiber, S.(12);
Created: Friday, 11 February 2022, 3:52 PM
OP17: Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Feagan, B.G.(1)*;Horst, S.(2);Dryden, G.(3);Lindsay, J.O.(4);Ferrante, M.(5);Dubenco, E.(6);Lacerda, A.P.(6);Ford, S.(6);Anyanwu, S.I.(6);Zhou, Q.(6);Liu, J.(6);Chen, M.(7);Schreiber, S.(8);
Created: Friday, 14 July 2023, 10:43 AM
OP18 Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease: The SuPREMe-CD study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Luglio, A. Rispo, N. Imperatore, A. Amendola, F.P. Tropeano, R. Peltrini, F. Castiglione, G.D. De Palma, L. Bucci

Created: Thursday, 30 January 2020, 10:12 AM
OP18: Disease course of Crohn's disease during the first ten years following diagnosis in a prospective European population-based inception cohort – the Epi-IBD cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wewer, M.D.(1)*;Salupere, R.(2);Kievit, H.A.L.(3);Nielsen, K.R.(4);Midjord, J.(4);Domislovic, V.(5);Krznarić, Ž.(5);Pedersen, N.(6);Kjeldsen, J.(7);Eriksson, C.(8);Halfvarson, J.(8);Talbot, A.(9);Sebastian, S.(9);Goldis, A.(10);Misra, R.(11);Arebi, N.(11);Ilus, T.(12);Oksanen, P.(12,13);Neuman, A.(14);Andersen, V.(15,16,17);Skamnelos, A.(18);Katsanos, K.H.(18);Platon, V.(19);Turcan, S.(19);Borg, B.(20);Ellul, P.(20);Kupcinskas, J.(21);Kiudelis, G.(21);Yzet, C.(22);Fumery, M.(22);Kaimakliotis, I.P.(23);Lorenzon, G.(24);D'Inca, R.(24);Hernandez, V.(25,26);Fernandez, A.(27);Langholz, E.(28);Munkholm, P.(29);Burisch, J.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP18: Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn’s Disease: Results from the phase 2 DIVERGENCE 2 study
Year: 2022
Source: ECCO'22
Authors: Reinisch , W.(1);Colombel , J.F.(2);D’Haens , G.R.(3);Rimola , J.(4);DeHaas-Amatsaleh , A.(5);McKevitt , M.(6);Ren , X.(6);Serone , A.(6);Schwartz , D.A.(7);Gecse , K.B.(3);
Created: Friday, 11 February 2022, 3:52 PM
OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Assa*1, M. Matar2, D. Turner3, E. Broide4, B. Weiss5, O. Ledder6, A. Guz Mark2, F. Rinawi2, S. Cohen7, C. Topf Olivestone8, R. Shaoul9, B. Yerushalmi10, R. Shamir2

Created: Friday, 22 February 2019, 9:41 AM
OP18: Treatment of perianal fistulas in Crohn’s Disease: Surgical closure after anti-TNF induction treatment versus anti-TNF without surgery (PISA II) - A patient preference RCT
Year: 2021
Source: ECCO'21 Virtual
Authors: Meima - van Praag, E.(1);van Rijn, K.(2);Snijder, A.(3);Wasmann, K.(4);Stoker, J.(2);D'Haens, G.(3);Gecse, K.(3);Gerhards, M.(5);Jansen, J.(6);Pronk, A.(7);van Tyl, S.(8);Zimmerman, D.(9);Bruin, K.(10);Spinelli, A.(11);Danese, S.(12);van der Bilt, J.(13);Mundt, M.(14);Bemelman, W.(1);Buskens, C.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP19 Perinatal factors do not affect paediatric inflammatory bowel disease risk: A Scottish Nationwide Cohort study using administrative health data 1981–2017
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Burgess1,2, C. Schnier3, I. Chalmers4, R.K. Russell5, R. Hansen5, P. Henderson1,2, R. Wood6,7, D.C. Wilson1,2

Created: Thursday, 30 January 2020, 10:12 AM
OP19: Classifying perianal fistulising Crohn’s Disease: An expert-consensus to guide decision-making in daily practice and clinical trials
Year: 2022
Source: ECCO'22
Authors: Geldof, J.(1);Iqbal, N.(2);LeBlanc, J.F.(3);Sawyer, R.(4);Buskens, C.(5);Bemelman, W.(5);Gecse, K.(6);Lundby, L.(7);Lightner, A.L.(8);Danese, S.(9);Spinelli, A.(10);Carvello, M.(10);Faiz, O.(11);Warusavitarne, J.(11);Lung, P.(12);De Looze, D.(13);D’Hoore, A.(14);Vermeire, S.(15);Hart, A.(3);Tozer, P.(16);
Created: Friday, 11 February 2022, 3:52 PM
OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

Y. Haberman*1,2, R. Karns2, P. Dexheimer2, M. Schirmer3, T. Braun1, M. Collins2, A. Mo4, M. Rosen2, N. Gotman5, PROTECT Study group, S. Kugathasan6, T. D. Walters7, G. Gibson4, S. Davis Thomas5, C. Huttenhower8, R. J. Xavier9, J. S. Hyams10, L. A. Denson2

Created: Friday, 22 February 2019, 9:41 AM
OP19: Disease course and treatment outcomes of early resected Crohn's Disease patients: A Danish nationwide cohort study from 1997 to 2015
Year: 2021
Source: ECCO'21 Virtual
Authors: Sarikaya, M.(1);Zhao, M.(2);Bendtsen, F.(1,2);Burisch, J.(2)
Created: Wednesday, 2 June 2021, 4:12 PM
OP19: Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fiorino, G.(1)*;
Created: Friday, 14 July 2023, 10:43 AM
OP20 The gut microbiota during biological therapy for inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Caenepeel1, S. Viera-Silva2, B. Verstockt3, K. Machiels3, N.A. Davani3, J. Sabino3,4, M. Ferrante3,4, J. Raes2, S. Vermeire3,4

Created: Thursday, 30 January 2020, 10:12 AM
OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Lewis*1, R. Jeffrey1, T. Kumagai1, C. J. Hawkey2, M. M. Clark2, M. Allez3, J. Satsangi4, G. Rogler5, A. Silver1, J. O. Lindsay6

Created: Friday, 22 February 2019, 9:41 AM
OP20: Perianal fistulas are characterised by expansion of interleukin-22 producing invariant natural killer T-cells and CD4+ T-cells which drive dysregulation of the extracellular matrix
Year: 2022
Source: ECCO'22
Authors: Constable, L.(1,2);Iqbal, N.(3,4);Cozzetto, D.(1);Hart , A.(3,4);Tozer, P.(3,4);Powell, N.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP20: Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study
Year: 2021
Source: ECCO'21 Virtual
Authors: Chaparro, M.(1);Garre, A.(1);Núñez Ortiz , A.(2);Diz-Lois Palomares, M.T.(3);Rodríguez, C.(4);Riestra, S.(5);Vela, M.(6); Benítez, J.M.(7);Fernández Salgado, E.(8);Sánchez Rodríguez, E.(9);Hernández, V.(10);Ferreiro-Iglesias, R.(11);Ponferrada Díaz, Á.(12);Barrio, J.(13); Huguet, J.M.(14);Arias, L.(15);Martín-Arranz, M.D.(16);Calvet, X.(17);Ginard, D.(18);Alonso-Abreu, I.(19);Fernández-Salazar, L.(20);Varela Trastoy, P.(21);Rivero, M.(22);Vera-Mendoza, I.(23);Vega, P.(24);Navarro, P.(25);Sierra, M.(26); Cabriada, J.L.(27);Aguas, M.(28);Vicente, R.(29);Navarro-Llavat, M.(30);Echarri, A.(31);Gomollón, F.(32);Guerra del Río, E.(33);Casanova, M.J.(1);Spicakova, K.(34);Ortiz de Zarate, J.(35);Alonso-Galán, H.(36);Barreiro-de Acosta, M.(11);Gisbert, J.P.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP20: The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Haens, G.(1)*;Tran, J.(2,3);Danese, S.(4);Rubin, D.T.(5);Aoyama, N.(6);Lügering, A.(7);Klaff, J.(3);Xuan, S.(3);Ilo, D.(3);Sanchez Gonzalez, Y.(3);Panes, J.(8);
Created: Friday, 14 July 2023, 10:43 AM
OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Nice1, N. Chanchlani2, H. Green2, C. Bewshea2, N. Kennedy2, T. Ahmad2, J. Goodhand2, T. McDonald1, M. Perry1

Created: Thursday, 30 January 2020, 10:12 AM
OP21: ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Vermeire1, X. Hébuterne2, P. Napora3, M. Wisniewska-Jarosinska4, G. Kiss5, A. Bourreille6, Z. Przemysław7, J. Nitcheu8, P. Gineste8, J-M. Steens*8, H. Ehrlich8

Created: Friday, 22 February 2019, 9:41 AM